The board of directors of Doseology Sciences Inc. (CNSX:MOOD), with the support of management, has initiated a review process to explore and evaluate a broad range of strategic alternatives. The strategic review process will encompass an evaluation of the Company's current strategic direction, operations, market valuation and capital structure and will consider appropriate alternatives for the Company, which may include one or more of the following: continuation as a stand-alone public company, strategic investor participation, acquisition by or a merger with an industry partner that may involve all or part of the Company's business or assets, and any other strategic alternatives that may be identified during the strategic review. The Board continues to support the Company's current strategic priorities.

However, the Board believes that, given the current state of the capital markets and the evolving landscape in our industry, a broad review of strategic alternatives is appropriate and in the best interest of the Company,' said Ralph Olson, Chief Executive Officer of the company and Chairman of the Board. While the strategic review process is ongoing, the company intends to continue to pursue its core strategic objectives so as to maintain and enhance the value of its current business and operations. Other than as described in this release, the company has not made any decisions related to strategic alternatives at this time and there can be no assurance that the evaluation of strategic alternatives will result in any transaction proceeding or change in strategy.

The Company does not intend to comment further unless and until further disclosure is appropriate or necessary.